HR
Healthcare Realty Trust Incorporated
$21.25
-0.07
(-0.33%)
Mkt Cap
7.45B
Volume
4,114,219
52W Range
15.29-21.475
Sector
Real Estate
Beta
0.82
EPS (TTM)
-0.58
P/E Ratio
-23.87
Revenue (TTM)
1.16B
Rev Growth (5Y)
+9.9%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$19.92
Overvalued
weak signal
6.7% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Real Estate Investment Trust
30.0 / 100 pillar composite (overridden)
A real-estate investment trust — graded A–F vs. similar companies.
Company Description
Healthcare Realty Trust operates as a Real Estate Investment Trust (REIT), specializing in the acquisition, development, financing, and active management of income-generating real estate assets, predominantly serving outpatient healthcare providers throughout the United States. By September 30, 2020, its extensive portfolio comprised 211 properties located across 24 states, collectively spanning 15.5 million square feet and valued at approximately $5.5 billion. The company further provided comprehensive leasing and property management solutions for 11.9 million square feet nationwide.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.18B | 1.27B | 1.34B | 932.64M | 534.82M | 735.07M | 693.63M | 695.30M | 613.11M | 460.48M | 403.41M | 371.05M |
| Net Income | (246.07M) | (654.49M) | (278.26M) | 40.90M | 66.66M | 52.62M | 30.15M | 213.46M | 63.92M | 49.95M | 32.93M | 45.37M |
| EPS | -0.71 | -1.81 | -0.74 | 0.15 | 0.45 | 0.24 | 0.15 | 1.04 | 0.35 | 0.34 | 0.26 | 0.38 |
| Free Cash Flow | 126.94M | 252.64M | 268.79M | 109.20M | 131.94M | 376.13M | 148.47M | 137.55M | 99.15M | 79.84M | 111.61M | 54.70M |
| FCF / Share | 0.36 | 0.69 | 0.71 | 0.43 | 0.93 | 1.72 | 0.72 | 0.67 | 0.55 | 0.58 | 0.89 | 0.46 |
| Operating CF | 457.10M | 501.62M | 499.82M | 272.75M | 232.63M | 470.09M | 213.14M | 208.35M | 179.77M | 151.27M | 160.38M | 125.37M |
| Total Assets | 9.21B | 10.65B | 12.64B | 13.85B | 4.26B | 3.81B | 3.56B | 3.19B | 3.19B | 3.04B | 2.82B | 2.76B |
| Total Debt | 4.15B | 4.96B | 5.30B | 5.70B | 1.92B | 1.71B | 1.52B | 1.35B | 1.28B | 1.26B | 1.43B | 1.40B |
| Cash & Equiv | 26.17M | 68.92M | 25.70M | 60.96M | 13.18M | 15.30M | 657,000 | 8.38M | 6.21M | 5.41M | 4.10M | 3.52M |
| Book Value | 4.62B | 5.23B | 6.82B | 7.57B | 2.19B | 1.95B | 1.90B | 1.72B | 1.79B | 1.65B | 1.24B | 1.22B |
| Return on Equity | -0.05 | -0.13 | -0.04 | 0.01 | 0.03 | 0.03 | 0.02 | 0.12 | 0.04 | 0.03 | 0.03 | 0.04 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 278.99M | 286.30M | 297.76M | 297.50M | 298.98M | 309.77M | 315.42M | 316.32M | 326.81M | 330.44M | 342.26M | 338.14M |
| Net Income | (56,000) | 14.39M | (57.74M) | (157.85M) | (44.87M) | (106.85M) | (93.02M) | (143.78M) | (310.84M) | (40.53M) | (67.84M) | (82.76M) |
| EPS | -0.00 | 0.04 | -0.17 | -0.45 | -0.13 | -0.31 | -0.26 | -0.39 | -0.82 | -0.11 | -0.18 | -0.22 |
| Free Cash Flow | (8.28M) | 45.79M | 24.93M | 77.56M | (21.34M) | 75.77M | 50.33M | 100.77M | 25.76M | 53.16M | 55.32M | 151.28M |
| FCF / Share | -0.02 | 0.13 | 0.07 | 0.22 | -0.06 | 0.22 | 0.14 | 0.27 | 0.07 | 0.14 | 0.15 | 0.40 |
| Operating CF | 52.88M | 132.34M | 113.75M | 163.22M | 47.79M | 138.01M | 119.30M | 168.15M | 76.15M | 127.32M | 118.18M | 185.13M |
| Total Assets | 9.15B | 9.21B | 9.86B | 10.24B | 10.50B | 10.65B | 11.24B | 11.80B | 12.28B | 12.64B | 13.10B | 13.39B |
| Total Debt | 4.34B | 4.15B | 4.72B | 4.97B | 5.03B | 4.96B | 5.26B | 5.45B | 5.41B | 5.30B | 5.57B | 5.69B |
| Cash & Equiv | 26.23M | 26.17M | 43.34M | 25.51M | 25.72M | 68.92M | 22.80M | 41.77M | 26.17M | 25.70M | 24.67M | 35.90M |
| Book Value | 4.44B | 4.62B | 4.68B | 4.82B | 5.08B | 5.23B | 5.52B | 5.89B | 6.42B | 6.82B | 7.00B | 7.18B |
| Return on Equity | -0.00 | 0.00 | -0.01 | -0.03 | -0.01 | -0.02 | -0.02 | -0.02 | -0.05 | -0.01 | -0.01 | -0.01 |
HR News
Healthcare Realty Trust Announces Second Quarter Earnings Release Date and Conference Call
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
New Strong Buy Stocks for June 8th
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Healthcare Realty Trust: Betting On Outpatient Demand Growth, Lower Operator Risk (Upgrade)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
H&R Real Estate Investment Trust (HR.UN:CA) Q1 2026 Earnings Call Transcript
D2L Survey Reveals How AI is Beginning to Reshape Entry-Level Work and the Talent Pipeline